a pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography：一个试点研究高剂量的烟酸对动脉壁的炎症使用氟脱氧葡萄糖正电子发射断层扫描的影响.pdfVIP

A Pilot Trial to Examine the Effect of High-Dose Niacin on Arterial Wall Inflammation Using Fluorodeoxyglucose Positron Emission Tomography Emil M. deGoma, MD, Ali Salavati, MD, MPH, Russell T. Shinohara, PhD, Babak Saboury, MD, MPH, Laura Pollan, MPH, Marisa Schoen, BA, Drew A. Torigian, MD, MA, Emile R. Mohler, MD, Richard L. Dunbar, MD, Harold I. Litt, MD, PhD, John Woo, MD, Daniel J. Rader, MD, Abass Alavi, MD, PhD, Nehal N. Mehta, MD, MSCE Rationale and Objectives: Although studies have reported direct inhibition of inflammatory pathways with niacin, the effect of niacin on arterial wall inflammation remains unknown. We examined the effect of niacin on arterial 18F-fluorodeoxyglucose (FDG)–positron emission tomography (PET)/computed tomography (CT). Materials and Methods: Nine statin-treated patients with coronary disease were randomized to niacin 6000 mg/day or placebo. FDG- PET/CT and lipids were assessed at baseline and at 12 weeks. FDG was quantified in the aorta, right carotid artery, and left carotid artery as the target-to-background ratio (TBR) and target-to-background difference (TBD). Results: Eight patients completed the study. No significant changes in FDG measured by aortic, left carotid, or right carotid TBR or TBD were seen in either group. Compared to baseline, niacin-treated subjects exhibited a significant 29% reduction in low-density lipoprotein cholesterol (LDL-C; 95% confidence interval [CI], 50% to 8%; P = .01) and a nonsignificant 29% reduction in LDL particle number (LDL-P; 95% CI, 58% to 0.2%; P = .07). A nonsignificant 11% increase in HDL-C (95% CI, 15% to 37%; P = .30) and 8% decrease in HDL-